Indoco Remedies Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3sz4jvsnlx4xwysgcvotdn8e.pdf

Key Takeaways


The Sterile Plant Warning Letter: Impact & Remediation

Aditi Panandikar: "And I have seen at least that for a few pennies, they have not moved because the partnership and sort of logistic kind of support, which we have faltered for the first time in 20 years where we probably have not given people what they have wanted. This is the first time it has happened. And I am very hopeful that we should not lose long-term business because of this."

Margin Compression: Anatomy of the Q3 Shock

Aditi Panandikar: "So we had said very clearly that this year, we were confident of maintaining close to 13% -- between 13% and 14%, but that has gone for a toss."

Master Manufacturing Plan: The Other Supply Disruption


Domestic Formulations: The Steady Anchor


Regulated Markets: US & EU Structure


Guidance & Commitments

CommitmentSpecificsTimeline
EU supply normalizationSolid orals supplies from Baddi and Goa resume; Europe "back on its feet"Q4 FY25
US business partly impactedWarning letter effect continues to constrain US suppliesQ4 FY25
Remediation cost peakBulk of remediation spending flows through P&LQ4 FY25 and Q1 FY26
Margin recovery to 13%Possible early signs of returning to 13% EBITDAQ3 FY26
Warning letter resolutionNo commitment; "hope FDA will allow more"No timeline given
Sterile manufacturing diversificationAlternative sterile manufacturing locations being explored"Will take some time"

Key Metrics

MetricQ3 FY25
Net revenue₹364.9 cr, compared to ₹448.4 cr in Q3 FY24
EBITDA₹20.1 cr, 5.5% of net sales, compared to ₹65.3 cr (14.6%) in Q3 FY24
EBITDA margin (9-month basis)10.5%–11%, down from 13% average earlier in the year
Domestic formulation revenue₹224.2 cr, grew 5.5% YoY from ₹212.6 cr
International formulation revenue₹107.4 cr, compared to ₹194.7 cr in Q3 FY24
Regulated markets revenue₹68.4 cr, compared to ₹147.5 cr in Q3 FY24
US business revenue₹28 cr, compared to ₹86.3 cr in Q3 FY24
Europe revenue₹35.4 cr, compared to ₹58.2 cr in Q3 FY24
Emerging markets revenue₹39 cr, compared to ₹47.2 cr in Q3 FY24
API business revenue₹28 cr
Sales drop from regulated markets (YoY)~₹90 cr in sales and revenues
Order book (international formulations, Europe and US)~₹180 cr
Cyclopam brand size (MAC basis, IQVIA)₹175 cr, with growth in excess of 20%
New introductions share of top line4.8%, versus industry benchmark of 2.8%
FPP unrecovered fixed cost~₹6–7 cr per quarter
Capex incurred in current year~₹200 cr, including new machines, upgradation, advances
Chronic mix9%–10% of portfolio